Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. Issue 1 (29th October 2020)

• Record Type: Journal Article
• Authors: Coomans, Marijke B; Dirven, Linda; Aaronson, Neil K; Baumert, Brigitta G; van den Bent, Martin; Bottomley, Andrew; Brandes, Alba A; Chinot, Olivier; Coens, Corneel; Gorlia, Thierry; Herrlinger, Ulrich; Keime-Guibert, Florence; Malmström, Annika; Martinelli, Francesca; Sloan, Jeff A; Stupp, Roger; Talacchi, Andrea; Weller, Michael; Wick, Wolfgang; Reijneveld, Jaap C; Taphoorn, Martin J B
• Is Part Of: Neuro-oncology advances. Volume 2:Issue 1(2020)
• Publication Date: 2020-10-29
• Subjects: glioma -- joint model -- net clinical benefit -- quality of life -- survival; 616.99481
• DOI: 10.1093/noajnl/vdaa147
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Background: Two methods combining survival and health-related quality of life (HRQoL) data in glioma trials to calculate the "net clinical benefit" were evaluated: Quality-adjusted effect sizes (QASES) and joint modeling (JM). Methods: The net clinical benefit in two trials was calculated as proof of concept for other trials. With the QASES method, effect sizes for differences in progression-free survival (PFS) or overall survival (OS) and HRQoL between the experimental arm and standard treatment arm were calculated, while the relative emphasis placed on survival/HRQoL varied. JM allows simultaneous modeling of HRQoL and OS/PFS. Results: In the EORTC 26951 trial, combined radiochemotherapy significantly prolonged OS (difference 11.7 months), but also resulted in more patients experiencing clinically relevant worsening (≥10 points) in appetite loss and nausea/vomiting shortly after treatment. Using QASES, the survival benefit of additional procarbazine, lomustine, and vincristine (PCV) decreased from 42.3 months to 29.5 and 28.2 months when accounting for appetite loss and nausea/vomiting, respectively. JM analyses resulted in a loss of the beneficial effect of additional PCV between 13% and 24% when adjusting for different HRQoL parameters. The EORTC 22033 trial showed no significant PFS difference between radiotherapy or temozolomide alone (46 vs 39 months), nor clinically relevant differences in HRQoL. JM analyses also showed no significant association between PFS and HRQoL scales/items, whereas QASES showed that temozolomide alone was more favorable when considering symptom burden (47–49 instead of 39 months). Conclusions: Both methods resulted in different outcomes, but adjusting for the impact of treatment on HRQoL resulted in theoretically reduced survival benefits.